Search company, investor...

Executives

4

Board of Directors

2

Salutaris Medical Devices Management Team

4 Team Members

Salutaris Medical Devices has 4 executives. Salutaris Medical Devices's founder is Michael Voevodsky. Salutaris Medical Devices's is .

Name

Work History

Title

Status

Michael Voevodsky

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michael Voevodsky

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Salutaris Medical Devices Board of Directors

2 Board of directors

Salutaris Medical Devices has 2 board of directors, including Richard Love.

Name

Firm

Work History

Other Seats

Richard Love

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Jos&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;e and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer.</br> </br> Dr. Sawyerss work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyerss key role in the clinical development of imatinib (Gleevec&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing.</br> </br> Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Salutaris Medical Devices

William Lomicka

Salutaris Medical Devices

Name

Richard Love

William Lomicka

Firm

Work History

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Jos&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;e and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer.</br> </br> Dr. Sawyerss work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyerss key role in the clinical development of imatinib (Gleevec&Atilde;&macr;&Acirc;&iquest;&Acirc;&frac12;), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing.</br> </br> Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Other Seats

Salutaris Medical Devices

Salutaris Medical Devices

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Salutaris Medical Devices to Competitors

BioWave Logo
BioWave

BioWave is a company that focuses on the development of non-opioid, patented pain blocking technology in the healthcare industry. The company's main offerings include wearable devices that deliver high-frequency neurostimulation to pain nerves, inhibiting the propagation of action potential along the nerve and blocking the transmission of pain signals to the brain. This technology is primarily used in the sports medicine and chronic pain management sectors. It was founded in 1997 and is based in Norwalk, Connecticut.

A
AllTranz

AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.

T
Trigemina

Trigemina focuses on developing innovative therapies in the pharmaceutical industry, specifically targeting chronic migraine and neuropathic pain without the use of opioids. The company's main offerings include non-sedating, cognition neutral neurological therapies that leverage novel naso-cerebral delivery systems to provide relief. It is based in Moraga, California.

M
MetaCure

MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

A
Atritech

Atritech has developed the WATCHMAN, an implantable device designed to capture clots that may form in the left atrial appendage of patients with atrial fibrillation, thereby aiming to reduce the risk of stroke and eliminating the need for long-term use of blood thinning medications.

S
SpineAlign Medical

SpineAlign Medical is an early-stage medical device company focused on developing minimally-invasive products for spine disorders. The company's main product is a nitinol implant designed to treat vertebral compression fractures, primarily affecting osteoporosis patients. SpineAlign Medical's technologies cater to the healthcare sector, with a focus on improving patient outcomes in spinal treatments. It is based in Pleasanton, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.